No Data
No Data
Amphastar Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Amphastar Pharma Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $66
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript Summary
Amphastar Pharmaceuticals Non-GAAP EPS of $0.96 Misses by $0.02, Revenue of $191.2M Misses by $3.49M
No Data
No Data
Shifting Gears : all the good shares on his side
Simon 5183 : The lower Trump's stock price, the greater the pressure from Financial Street, which means that Trump's chances of winning are greater.
dookiro : Will interest fed rate drop drastically if Trump were to win?
D3VIN dookiro : no
Mr Neitaniel :
View more comments...